Nemaura Medical (NASDAQ: NMRD), a company focused on providing digital and glucose monitoring solutions for patients dealing with diabetes, pays close attention to essential information and research that impacts the successful implementation of its solutions. Recently, the company tweeted about a study published by Dove Medical Press that included a survey of 105 participants with type 2 diabetes. The report indicated that most participants were interested in using electronic methods to communicate more with their doctors between visits. “These findings are particularly interesting to Nemaura, which has developed a proprietary technology that replaces traditional invasive methods of glucose monitoring that can be useful in disease management and diagnosis,” reads a recent article. Its BEAT(R) solution allows for continuous remote monitoring of chronic diseases and health conditions. It is designed to help people with diabetes manage their condition and potentially reverse type 2 diabetes using a combination of data from a wearable sensor and digital intervention and coaching. BEAT is combined with the company’s proprietary sugarBEAT(R) sensor platform, which is the world’s first non-invasive daily-wear continuous glucose monitoring device designed for use by people with both type 1 and type 2 diabetes as well as pre-diabetes, to trend glucose profiles. “This commitment to offering solutions designed to support patients in their treatment plans makes Nemaura distinctive.”
To view the full article, visit https://ibn.fm/fIATQ
About Nemaura Medical Inc.
Nemaura Medical is a medical technology company developing and commercializing noninvasive wearable diagnostic devices. The company is currently commercializing sugarBEAT(R) and proBEAT(TM). sugarBEAT, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (“CGM”) providing actionable insights derived from real-time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT to the U.S. FDA. proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital health care subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT(R) diabetes program. The company sits at the intersection of the global type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023. For more information, please visit www.NemauraMedical.com.
NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork